UNLOCKING THE POTENTIAL OF GENE THERAPY FOR ALL
About
Science & Innovation
THE CAPSIDA APPROACH
Capsida integrates all capabilities needed to surpass the challenges of gene therapy.
Capsid Engineering and Preclinical
At Capsida, the scale at which we have engineered capsids is unrivaled. Using our fully industrialized and roboticized screening method, our scientists assess large, diverse engineered capsid libraries for CNS and the eye in non-human primates to quickly identify optimal capsids for disease targets. To quickly advance our mission of providing meaningful therapeutic opportunities for patients with unmet medical need, Capsida characterizes the novel mechanisms of action that enable our engineered capsids to cross biological barriers, optimizes cargo and evolves preclinical disease proof-of-concept in parallel with capsid engineering. Our engineered capsids can be optimized to deliver a broad range of cargo modalities.
Manufacturing Operations
We have built state-of-the-art cGMP manufacturing capabilities to perform everything in-house. We streamline the entire process, from selecting our therapies for manufacturability through scalable process development. Ultimately, this helps us get therapeutics to patients sooner.
Team
Capsida’s founding technology originated in the lab of Caltech’s Viviana Gradinaru, Ph.D., Professor of Neurosciences and Biological Engineering at the Tianqiao and Chrissy Chen Institute of Neuroscience. Founded in 2019, Capsida is financed by Versant Ventures and Westlake Village BioPartners and has entered into strategic collaborations with AbbVie, CRISPR Therapeutics, and Lilly’s Gene Therapy Division.
Our leaders have decades of experience in the biopharmaceutical industry and expertise in AAV biology and biologics manufacturing.
Partnering
“Our partnerships with leading global biopharmaceutical companies are key to Capsida achieving its vision of being able to reach more potential patients in need with our enabling genetic medicines.”
Bethany Mancilla, Chief Business Officer
Our goal is to apply the strength of our targeted genetic medicine platform to develop a new generation of transformative therapies. Since our inception, we have entered into strategic collaborations with AbbVie, CRISPR Therapeutics, and Lilly’s Gene Therapy Division.
